DERMAGO secures over 1.6 million euros in capital through Companisto financing round

Growth spurt for DERMAGO: Second financing round with Companisto completed - investments for product portfolio and international expansion

The pharmaceutical startup DERMAGO has successfully completed a financing round on the private investor network Companisto, raising 1.6 million euros in capital. Around 370 Companists and co-investors participated in this round. DERMAGO, which specializes in prescription dermatologicals, will use the capital to promote access to new dermatological drugs.

The DERMAGO Group, consisting of Aresus Pharma, DEGODE Pharma and Skin Care Pharma, focuses on the production and distribution of drugs for skin diseases such as acne, atopic dermatitis and genital warts. The company markets its products worldwide through an established distribution network in cooperation with international pharmaceutical companies.

Second successful round with Companisto

The financing round marks another milestone for the DERMAGO Group, which has already completed a consolidation of its three subsidiaries in 2021 in order to exploit synergies in various areas. This is already the company's second successful financing round with Companisto.

Companisto, the private investor network in the D-A-CH region, has so far committed 223.1 million euros in over 310 financing rounds. With a network of 149,000 private investors and a digitally organized Business Angel Club, Companisto has been supporting startups as a venture capital provider for seven years.

Expansion of own laboratory planned

The team around founder Sven Schimansky-Wabra plans to use the fresh funds to expand the product portfolio, develop the company's own pharmaceutical laboratory and strengthen international sales. The participation of around 370 investors not only provides financial support, but also opens up access to a broad network of knowledge and experience. The capital gained will be used primarily for the further development of Veregen®, a drug for the treatment of actinic keratosis, and to support clinical studies.

DERMAGO GmbH, as a service company, focuses on the development of generic versions and original preparations of prescription dermatological drugs. In addition to the independent implementation of the pharmaceutical approval process, the company also offers consulting activities, scientific assessments and comprehensive studies in the field of dermatological pharmaceuticals.